Search clinical trials for: Montanide ISA51

Total 107 results

Lars Møller Pedersen
IO Biotech

Completed

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Chronic Lymphocytic Leukemia

Denmark
Kinki University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Gastric Cancer

Japan
Cliniques universitaires Saint-Luc- Université...
Immutep S.A.S.

Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Melanoma

Belgium
Masonic Cancer Center, University of Minnesota

Terminated

Vaccination With Tetanus and KLH to Assess Immune Responses.

Cancer

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

Breast Neoplasms | Prostatic Neoplasms | Ovarian Neoplasms

United States
NYU Langone Health

Completed

Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors

Tumors, Central Nervous System

United States
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreas Neoplasms

Japan
National Institute of Allergy and Infectious Diseases...

Completed

PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria

Plasmodium Falciparum | Plasmodium Vivax Malaria

United States
University of Southern California

Terminated

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

Melanoma

United States
Sellas Life Sciences Group
United States Department of Defense

Completed

WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Malignant Pleural Mesothelioma

United States
Swiss Tropical & Public Health Institute
Radboud University Medical Center; Centre Hospitalier Universitaire Vaudois

Completed

Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (DG002)

Plasmodium Falciparum Malaria

Switzerland
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of Stage III/IV Melanoma Patients

Melanoma

Switzerland
University College, London
AstraZeneca; Shionogi

Recruiting

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE)

Bladder Cancer

United Kingdom
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
PATH; World Health Organization; Xinhua Hospital, Shanghai Jiao Tong University... and other collaborators

Completed

A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

Prophylaxis Against Plasmodium Falciparum Malaria

China
University of Arkansas

Withdrawn

The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients

Neoplasms by Site | Metastatic Cancer
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Breast Cancer

Japan
Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Tumors

United States
University Hospital Tuebingen

Available

Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients (InHeVac01)

Cancer
Merck KGaA, Darmstadt, Germany

Completed

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Dr. Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Melanoma

United States
Oryx GmbH & Co. KG

Completed

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)

HPV-induced Cancers

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
University of Virginia

Completed

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38 (MEL38)

Melanoma

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
National Cancer Institute (NCI)

Completed

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Melanoma

United States
University of Arkansas
United States Department of Defense

Completed

Vaccination of High Risk Breast Cancer Patients

Stage IV Breast Cancer

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI); University of Virginia; Oncovir, Inc.

Completed

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

Melanoma

United States
Dartmouth-Hitchcock Medical Center
University of Vermont

Terminated

Derivation of Tumor Specific Hybridomas

Glioblastoma
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Breast Cancer

United States
Bioven Sdn. Bhd.

Terminated

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV (NSCLC)

Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV

Malaysia
Malaria Vaccine and Drug Development Center

Not yet recruiting

Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers

Malaria, Vivax

Colombia
Malaria Vaccine and Drug Development Center
The Administrative Department of Science, Technology and Innovation, Colciencias

Completed

Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax

Malaria

Colombia
Benovus Bio, Inc.

Unknown

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Multiple Myeloma (MM) | Smoldering Multiple Myeloma (sMM)

United States
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Terminated

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Autoimmune Disorders

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Colorectal Cancer

United States
Ludwig Institute for Cancer Research

Completed

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

Cancer | Neoplasm

Germany
Centre Hospitalier Universitaire Vaudois

Completed

Immunotherapy of Melanoma Patients

Melanoma

Switzerland
Abramson Cancer Center of the University of Pennsylvania
Ovarian Cancer Research Center

Terminated

Autologous OC-L Vaccine and Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Primary Ovarian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Innovive Pharmaceuticals

Completed

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Leukemia

United States
David Peereboom

Active, not recruiting

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Recurrent Glioblastoma

United States
University Hospital Tuebingen

Unknown

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides (UroRCC)

Renal Cell Cancer | Advanced Renal Cell Cancer
National Cancer Institute (NCI)

Completed

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

High-Risk Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non-Small Cell Lung Carcinoma | Carcinomas

United States
University of Oxford

Recruiting

KLH Challenge to Explore the Human Immune Response

Immune Response

United Kingdom
Abramson Cancer Center of the University of Pennsylvania

Terminated

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Malaria Vaccine and Drug Development Center
Asoclinic Inmunología Ltda.; Centro médico Imbanaco

Completed

Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants (Fase1B)

Malaria, Vivax

Colombia
Nina Bhardwaj
Memorial Sloan Kettering Cancer Center; NYU Langone Health; Ludwig Institute... and other collaborators

Completed

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Melanoma

United States
National Cancer Institute (NCI)

Completed

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Recurrent Melanoma | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States

Search clinical trials for: Montanide ISA51

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations